A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

359

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Locally Advanced Solid TumorMetastatic Solid Tumor
Interventions
DRUG

Zidesamtinib (NVL-520)

Oral tablet of zidesamtinib (NVL-520)

Trial Locations (63)

1066

RECRUITING

Netherlands Cancer Institute, Amsterdam

2050

RECRUITING

Chris O'Brien Lifehouse, Camperdown

3000

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

RECRUITING

University Hospital Leuven, Leuven

10002

RECRUITING

National Taiwan University Hospital, Taipei

10016

RECRUITING

NYU Langone Health, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10408

RECRUITING

National Cancer Center, Gyeonggi-do

15006

RECRUITING

University Hospital of A Coruña, A Coruña

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

20007

RECRUITING

Georgetown University Medical Center, Washington D.C.

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20141

RECRUITING

Istituto Europeo di Oncologia, Milan

22031

RECRUITING

NEXT Oncology - Virginia Cancer Specialists, Fairfax

28007

RECRUITING

Gregorio Marañón Hospital, Madrid

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

28050

RECRUITING

Hospital Universitario HM Sanchinarro, Madrid

28204

RECRUITING

Atrium Health Levine Cancer Institute, Charlotte

31300

RECRUITING

Claudius Regaud Institute, Toulouse

33146

RECRUITING

University of Miami, Coral Gables

35128

RECRUITING

Istituto Oncologico Veneto, Padua

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

40201

RECRUITING

Chung Shan Medical University Hospital, Taichung

43210

RECRUITING

Ohio State University, Columbus

44000

RECRUITING

CHU de Nantes, Nantes

48121

RECRUITING

Ospedale Santa Maria delle Croci, Ravenna

48202

RECRUITING

Henry Ford Cancer Institute, Detroit

60121

RECRUITING

Università Politecnica Marche, Ancona

60637

RECRUITING

University of Chicago, Chicago

63110

RECRUITING

Washington University School of Medicine, St Louis

69008

RECRUITING

Centre Legon Berard, Lyon

70124

RECRUITING

IRCCS Istituto Tumori Giovanni Paolo II, Bari

77030

ACTIVE_NOT_RECRUITING

MD Anderson Cancer Center, Houston

80045

RECRUITING

University of Colorado Cancer Center, Denver

92868

RECRUITING

UCI Medical Center, Orange

94305

RECRUITING

Stanford Medicine, Palo Alto

94805

RECRUITING

Institute Gustave Roussy, Villejuif

95817

RECRUITING

UC Davis Comprehensive Cancer Center, Sacramento

98109

RECRUITING

University of Washington / Fred Hutchinson Cancer Center, Seattle

119074

RECRUITING

National University Hospital Singapore, Singapore

168583

RECRUITING

National Cancer Centre Singapore, Singapore

704017

RECRUITING

National Cheng Kung University Hospital, Tainan City

02114

RECRUITING

Mass General Hospital, Boston

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

T6G 1Z2

RECRUITING

Cross Cancer Institute, Edmonton

M5GG 1L7

RECRUITING

Princess Margaret Cancer Research, Toronto

Unknown

RECRUITING

Cologne University Hospital, Cologne

RECRUITING

University Medical Centre Groningen, Groningen

RECRUITING

Samsung Medical Center, Seoul

00128

RECRUITING

Istituto Nazionale Tumori Regina Elena, Rome

411-8777

RECRUITING

Shizuoka Cancer Center, Nakatogari

700-8558

RECRUITING

Okayama University Hospital, Okayama

577-8502

RECRUITING

Kindai University, Osaka

104-0045

RECRUITING

National Cancer Center Hospital, Tokyo

135-0063

RECRUITING

Japanese Foundation for Cancer Research, Tokyo

641-0012

RECRUITING

Wakayama Medical University Hospital, Wakayama

241-8515

RECRUITING

Kanagawa Cancer Center, Yokohama

03080

RECRUITING

Seoul National University Hospital, Seoul

03722

RECRUITING

Yonsei University Health System, Seoul

08017

RECRUITING

UOMI Cancer Center - Clinica Tres Torres, Barcelona

08035

RECRUITING

Vall d'Hebron University Hospital, Barcelona

SW3 6JJ

RECRUITING

Royal Marsden Hospital, London

M20 4BX

RECRUITING

Christie NHS Foundation Trust, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Nuvalent Inc.

INDUSTRY

NCT05118789 - A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Biotech Hunter | Biotech Hunter